Cure8

Why This Matters

This animal study suggests Antarctic krill oil may reduce inflammation and weight loss in a mouse model of ulcerative colitis and works alongside changes in gut microbiota and metabolites—findings that could inform future microbiota-targeted nutritional approaches for IBD.

Who Should Pay Attention

Researchers studying microbiome–host interactions or nutritional interventions in IBD; adult patients and caregivers interested in diet/supplement research (note: preclinical evidence only).

Study Snapshot

Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract

What To Know

This paper reports an animal (mouse) study combining molecular assays, transcriptomics, metabolomics, and 16S rRNA sequencing to evaluate AKO in dextran sulfate sodium (DSS)-induced colitis.

The authors describe reduced colitis symptoms and evidence that AKO affected the PI3K/Akt signaling pathway, shifted gut microbiota composition, and altered glycerophospholipid-related metabolite profiles.

These findings are preclinical and mechanistic: they show associations between AKO treatment, microbiome and metabolite changes, and reduced inflammation in mice, but do not establish safety or efficacy in humans with ulcerative colitis.

If you have UC or IBD and are considering supplements, discuss them with your clinician; this study alone does not support clinical use in humans.

Keep In Mind

This is a preclinical (mouse) study reported in an academic journal and the available content is abstract/partial. Results in animals do not directly translate to human benefit; safety, dosing, and clinical efficacy would require human trials.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Research paper Evidence type derived from source or registry metadata.
PublicationMarine Drugs
PublisherMDPI AG
AuthorsShuyin Yang, Xinnan Zhao, Tiantian Chen +6 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedAug 14, 2026, 12:00 AM
Content availableJournal abstract

Funding disclosed by the source: Central Public-interest Scientific Institution Basal Research Fund, CAFS, award 2026XT0203; Central Public-interest Scientific Institution Basal Research Fund, CAFS, award 2023TD52; CARS, award CARS-49

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →